Authors
Latest:
Future Directions for the Management of MigraineBradley Torphy, MD, and Julio R. Vieira, MD, share unmet needs and clinical pearls for the management of migraine.
Latest:
Unveiling the Role of Estrogen in Women's Cognitive Health: Lisa Mosconi, PhDThe director of the Weill Cornell Women’s Brain Initiative discussed emerging research that highlight the significant impact of sex hormones on women's brain health, and how it influences conditions like Alzheimer disease. [WATCH TIME: 8 minutes]
Latest:
Advice for Physicians and the Multiple Sclerosis CommunityThe panel shares final advice for the multiple sclerosis community.
Latest:
Intervening Early in MS With Exercise: Ulrik Dalgas, PhDThe professor of public health and sports science at Aarhus University shared his perspective on the potential to modify multiple sclerosis disease progression with lifestyle interventions. [WATCH TIME: 2 minutes]
Latest:
Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQThe rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]
Latest:
Unveiling the Connection Between Migraine and the Gut: Daping Yang, PhDThe postdoctoral researcher at Harvard Medical School discussed the relationship between sensory neurons and the neuropeptide CGRP in regulating gut immunity. [WATCH TIME: 6 minutes]
Latest:
Using SEEG Data to Decode Brain Activity for Decision-Making: Alexander C. Whiting, MDThe director of epilepsy surgery at Allegheny Health Network talked about recent advances in brain signal analysis with stereoelectroencephalography and its potential for transforming care for decision-making disorders. [WATCH TIME: 4 minutes]
Latest:
Looking Ahead: How Consensus Guidelines Will Shape the Future of SMA CareThis closing episode looks ahead to the future of SMA care, examining how updated best practices aim to accelerate access, optimize outcomes, and fuel ongoing progress.
Latest:
Innovation in Stroke Care and Expanding the Treatment Windows: Keith Churchwell, MD, FAHA, FACC, FACPThe president of the American Heart Association discussed how precision medicine, advanced imaging, and expanded treatment windows are transforming stroke care, as displayed at ISC 2025. [WATCH TIME: 5 minutes]
Latest:
Ways to Optimize Trials for ALS Drug Development: Richard Bedlack, MD, PhD, MSThe director of the Duke ALS Clinic at Duke Health discussed the advances in drug development for ALS and ways to evolve future trials to get optimal therapeutic benefit. [WATCH TIME: 3 minutes]
Latest:
Rethinking Alzheimer Diagnosis and Disease Staging: Clifford Jack, MDThe neuroradiologist at Mayo Clinic discussed the clinical and conceptual differences between Alzheimer disease diagnostic frameworks and how clinicians should prepare for a shifting treatment landscape. [WATCH TIME: 4 minutes]
Latest:
Continued Evolution of Deep Brain Stimulation in Neurology: Jonathan Jagid, MD; Brian Noga, PhDA pair of neurologists from the University of Miami Miller School of Medicine provided insight on the various ways deep brain stimulation has changed and the potential treatment opportunities that lie ahead. [WATCH TIME: 4 minutes]
Latest:
Effectiveness of Zavegepant in Treating Migraine With and Without Aura: Timothy Smith, MDThe chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]
Latest:
Clinical Validation and Real-World Impact of PrecivityAD2 Test for Alzheimer Diagnosis: Joel B. Braunstein, MDThe CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]
Latest:
Utilizing Aspirin to Lower Stroke Rates in Cerebral Amyloid Antipathy: Sheheryar Jamali, MDThe neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.
Latest:
Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MScThe chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]
Latest:
An Overview of Therapeutic Options for Amyotrophic Lateral SclerosisWith an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
Latest:
Best Practices for Collaborative Migraine CareDr Williams discusses best practices for taking care of patients with migraine in a collaborative manner.
Latest:
Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira AhmedThe executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]
Latest:
Resources for Sleep DisordersDrs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.
Latest:
A Changing Clinical Landscape: Promising Therapeutic Avenues in the Treatment of DIPG and Other Diffuse Midline GliomasA duo of experts from Weill Cornell Medicine talked about the advancements made in diffuse midline gliomas research and clinical trials that may offer new hope for improving its historically poor prognosis.
Latest:
Emerging Treatment Landscape and Future Outlook for Friedreich AtaxiaAn expert discusses how vatiquinone targets Friedreich ataxia in patients with balance issues by inhibiting 15-lipoxygenase to reduce oxidative stress. Novel dual-route gene therapy combines systemic IV and targeted dentate nuclei delivery, addressing both central and peripheral manifestations while potentially offering disease-modifying benefits.
Latest:
Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhDThe executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]
Latest:
Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MScThe pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Latest:
Lifestyle Change for Migraine Management: Practical Tips for the Neurologist and PCP, Part 2Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.
Latest:
Current and Future Landscape of Alzheimer Disease Treatment: Emergence of Disease Modifying TherapiesAfter years of failed drug development, the thoughts of disease-modifying therapies for Alzheimer disease are starting to become real.
Latest:
From Fibrosis to Function: Exploring New Pathways in Muscular Dystrophy ResearchNeuromuscular expert Matthew Alexander, PhD, explores the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.
Latest:
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MSAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
